News
NKTR
1.000
-2.91%
-0.030
Nektar presents preclinical data on NKTR-422 at ACR conference
TipRanks · 2d ago
Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic Inflammatory Conditions
Benzinga · 2d ago
Weekly Report: what happened at NKTR last week (1111-1115)?
Weekly Report · 3d ago
Multiple Catalysts Ahead For Nektar Therapeutics
Seeking Alpha · 6d ago
Nektar Therapeutics To Present At UBS Global Healthcare Conference; Webcast At 1:15 PM ET
NASDAQ · 11/13 17:18
Oppenheimer Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
TipRanks · 11/12 12:48
Weekly Report: what happened at NKTR last week (1104-1108)?
Weekly Report · 11/11 09:24
NEKTAR THERAPEUTICS FORM 10-Q
Press release · 11/08 22:42
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
NASDAQ · 11/08 17:02
Nektar Therapeutics Reports Stable Q3 Earnings for 2024
TipRanks · 11/08 05:09
Nektar Therapeutics reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/08 04:39
Nektar reports Q3 EPS (18c), consensus (20c)
TipRanks · 11/07 21:35
Nektar Therapeutics GAAP EPS of -$0.18 beats by $0.03, revenue of $24.12M beats by $5.84M
Seeking Alpha · 11/07 21:23
Press Release: Nektar Therapeutics Reports Third Quarter 2024 Financial Results
Dow Jones · 11/07 21:15
*Nektar Therapeutics 3Q Loss/Shr 18c >NKTR
Dow Jones · 11/07 21:15
Nektar releases promising phase 2 results for NKTR-255 in lymphopenia
Seeking Alpha · 11/07 18:30
Biotech Alert: Searches spiking for these stocks today
TipRanks · 11/07 15:55
Nektar: Q3 Earnings Snapshot
Barchart · 11/07 15:36
Nektar presents late-breaking results from Phase 2 Study of NKTR-255
TipRanks · 11/07 15:20
Nektar And Collaborators Present Late-Breaking Results From Phase 2 Study Of NKTR-255 For The Treatment Of Radiation Induced Lymphopenia In Locally Advanced Non-Small Cell Lung Cancer Patients At SITC Annual Meeting; Demonstrated Statistically Significant Lymphocyte Recovery Compared To Historical Controls At Week 8
Benzinga · 11/07 15:16
More
Webull provides a variety of real-time NKTR stock news. You can receive the latest news about Nektar Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About NKTR
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.